Table 1. Characteristics of the sample (N=53)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>40 (76.47%)</td>
</tr>
<tr>
<td>Age at diagnosis (years)</td>
<td>54.94 (11.68)</td>
</tr>
<tr>
<td>Active smoker</td>
<td>15 (32.33%)</td>
</tr>
<tr>
<td>ACPA positive</td>
<td>36 (67.32%)</td>
</tr>
<tr>
<td>mRF positive</td>
<td>44 (83.02%)</td>
</tr>
<tr>
<td>Nodules</td>
<td>11 (20.75%)</td>
</tr>
<tr>
<td>Extra-articular disease</td>
<td>11 (20.75%)</td>
</tr>
<tr>
<td>Erosions*</td>
<td>35 (74.47%)</td>
</tr>
<tr>
<td>Monotherapy at optimization</td>
<td>23 (43.4%)</td>
</tr>
<tr>
<td>bDMARD previous to OT</td>
<td>0.71 (0.97)</td>
</tr>
</tbody>
</table>

Optimized bDMARD

- ETN 20 (37.74%)
- ADA 16 (30.19%)
- ABA 7 (13.21%)
- TCZ 7 (13.21%)
- GOL 2 (3.77%)
- CZB 1 (1.89%)

DAS28 at diagnosis

- Diagnosis 4.88 (1.25)
- Beginning – 1st sDMARD 4.62 (1.6)
- Beginning – 1st bDMARD 4.98 (1.1)
- Beginning – opt sDMARD 4.67 (1.17)
- Optimization 1.88 (0.65)

Months from diagnosis to introduction of 1st sDMARD 19.67 (35.01)
Months from diagnosis to introduction of 1st bDMARD 38.75 (30.34)
Months from diagnosis to introduction of optimization 23.73 (22.47)

ACPA: anti-citrullinated protein antibodies; mRF: monoclonal rheumatoid factor; Erosions: presence of erosions at Optimization; bDMARD: biological DMARD; ETN: Etanercept; ADA: Adalimumab; ABA: Abatacept; TCZ: Tocilizumab; GOL: Golimumab; CZB: Certolizumab; Opt bDMARD: bDMARD optimized; csDMARD: conventional synthetic DMARD; Low activity: DAS28 < 3.2

Conclusion: OT is a therapeutic option from which some patients could benefit. Maintenance of OT may be related to early start of DMARDs. More studies are needed to define the characteristics of patients who can safely benefit from OT.
OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS UNDER TOCILIZUMAB AS FIRST DMARD: A REAL-LIFE MONOCENTRIC COHORT STUDY

P. R. Martins1, A. Martins2, D. Santos Oliveira1,3, D. Fonseca2, M. Rato3, F. Oliveira Pinheiro1, S. Garcia2, B. M. Fernandes1, L. Costa1, M. Bernardes3,1
1Centro Hospitalar Universitário do Algarve - Faro, Rheumatology, Faro, Portugal; 2Centro Hospitalar Universitário São João, Rheumatology, Porto, Portugal; 3Faculty of Medicine, University of Porto, Center for Health Technology and Services Research (CINTESIS), Porto, Portugal; 4C. H. Vila Nova de Gaia/Espinho, Rheumatology, Vila Nova de Gaia, Portugal

Background: Rheumatoid arthritis (RA) is one of the most frequent systemic inflammatory rheumatic diseases, being constantly assessed regarding new disease activity monitoring tools and new therapeutic targets and therapies. Tocilizumab (TCZ) is one of the latest biological disease-modifying antirheumatic drugs (bDMARDs) approved for RA treatments, usually as a second line agent in daily clinical practice.

Objectives: Evaluate the different disease and patient reported outcomes in patients undergoing treatment with tocilizumab as the first biologic therapy.

Methods: All patients with a definite RA diagnosis who had undergone treatment with TCZ as the first biologic therapy at a tertiary hospital's rheumatology department were included in this analysis. Diverse socio-demographic data, as well as disease and patient related outcomes were assessed at baseline, 6, and 12 months of treatment with TCZ, and posteriorly extracted from the Portuguese register of rheumatic diseases (Reuma.PT). Statistical analysis included non-parametric tests such as Wilcoxon test and univariate analysis using linear and logistic regression models.

Results: Fifty-one patients were included, 88.2% females, with a median age at introduction of TCZ of 53.5+/-10.4 years: mainly seropositive for either rheumatoid factor (66%) or anti-citrullinated peptide antibody (ACPA; 68%), with an erosive disease (75.6%) and concomitantly treated with a conventional synthetic disease modifying anti-rheumatic drug (csDMARD) (70.5%). During follow-up there was a statistically significant reduction at 6 and 12 months of TCZ treatment regarding DAS28 (4 variables) (4v) and DAS28(4v)-CRP scores (p < 0.001), SDAI (p < 0.001), CDAI (p < 0.001), 66/66 tender and swollen joint counts (TJC/SJC) (p < 0.001), ESR and CRP (p < 0.001), patient and physician VAS (p < 0.001) and HAQ score (p = 0.01 at 6 months and p < 0.01 at 12 months). Rheumatoid factor and ACPA serum levels weren't statistically different at 6 and 12 months of treatment with TCZ compared to the initial assessment, as well as the ACR responders at the same 6 months versus those at 12 months. A majority of patients showed good ACR20 response at 6 (52.6%) and 12 (66.3%) months, as well as moderate to high mean improvement in ACR core set measures at 6 (53.3±22.7) and 12 (54.3±25.2) months. Assessment of subsequent therapeutic maintenance showed that 75% of patients remained under tocilizumab with an average treatment duration of 48.8±37.7 months. Reasons for switch ranged from adverse effects (63.6%) to primary failure (18.2%) and secondary failure (18.2%). There was a significant reduction in DAS28(4v), DAS28(4v)-CRP, CDAI, SDAI, TJC and SJC, ESR, CRP, patient and physician VAS and HAQ scores between 6 and 12 months of therapy (p < 0.001). ACR and EULAR responses didn't differ significantly between assessments at 6 and 12 months. In the absence of a representative number of RA patients on TCZ monotherapy, it wasn't possible to draw conclusions about the need to use combined therapy with a csDMARD for better clinically significant response. A higher degree of ACR response at 6 months was associated with higher serum rheumatoid factor levels (OR 1.13, p < 0.05) at baseline, while a lower degree of response was seen with higher TJC (p = 0.05) and HAQ score (p < 0.01). ACR response at 12 months was lower in patients with erosive disease at baseline (p < 0.05). Regarding EULAR response criteria at 6 months, there was a negative correlation with higher TJC (p < 0.05), while at 12 months the negative trend was associated with ESR levels (p < 0.05) and HAQ scores (p < 0.05) at baseline.

Conclusion: There seems to be evidence of good therapeutic response to TCZ in bDMARD naive RA patients assessed at 6 months from baseline, without evidence of significant improvement of response measures further down the line. Basal serum rheumatoid factor levels, TJC, HAQ scores and the presence of erosive disease may have some predictive value on the therapeutic response. Further studies comparing TCZ as the first bDMARD in naive RA patients against TNF inhibitors are needed.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2021-eular.3045

AB0232
PREVALENCE OF INFECTIONS UNDER BIOThERAPY DURING RHEUMATOID ARTHRITIS

K. Baccouche1, R. Grassa1, S. Latsu2, O. Jornaa1, N. El Amn1, H. Zeglaou1, E. Bouajina1
1Farhat Hached Hospital, Rheumatology, Sousse, Tunisia

Background: Biologic therapies are emerging as a significant therapeutic option for many with debilitating inflammatory and autoimmune conditions including rheumatoid arthritis (RA). These biologic agents are highly effective in RA. Potential complications are dominated by infections.

Objectives: To evaluate the different infections occurred under biotherapies. Methods: This is a descriptive retrospective study including patients under biotherapy, hospitalized between 2000-2016 in the Rheumatology Department of Farhat Hached hospital in Sousse, Tunisia. We evaluated for each patient the different infections that had occurred, specifying the different types of biotherapy received.

Results: Fifty-one patients are included (54 women and 7 men). The average age was 55.33 years ±11.51 [34-81 years]. We found 47 infections in 40 patients (65.57%) with at least one infection under biotherapy: 41 women and 6 men with a mean age at 57.72 years [34-81 years]. Infections occurred under anti IL6 in 46.32%, Infliximab in 31.58%, anti CD20 in 11.58%, Etanercept in 7.3% and under Certolizumab in 3.16%. The infection was bacterial in 68.42%; 28 pulmonary infections, 8 otolaryngology infections, 14 urinary infections, 2 soft tissue abscesses, 13 cutaneous infections, 2 ocular infections. A viral origin of the infection was noted in 12.63% of cases. As for mycosis infections they represent 18.75% of the etiologies identified. The treatment was medical in 100% of cases and the evolution was favorable in all patients without resorting to the definitive discontinuation of biotherapies.

Conclusion: The infections reported in our series are much more frequent under anti IL6 treatment and bacteria are the most incriminating pathogenic agents in our patients.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2021-eular.3197

AB0233
REASONS AND RISK FACTOR FOR DISCONTINUATION OF BIOLOGIC AGENTS FOR RHEUMATOID ARTHRITIS PATIENTS IN LONG-TERM OBSERVATION

K. Terabe1, N. Takahashi1, S. Asai1, Y. Hirano2, Y. Kanayama3, T. Kojima1
1Nagoya University School of Medicine, Orthopedic Surgery, Nagoya, Japan; 2Toyohashi Municipal Hospital, Rheumatology, Toyohashi, Japan; 3Toyota Kosei Hospital, Orthopedic Surgery, Toyota, Japan

Background: Rheumatoid arthritis (RA) patients who failed a first biologic agent due to any reasons have the option of switching to a second one along with the strategy of biologic agent treatment. Patients go over switching to the next one at failing their biologic agent. On the other hand, there are some patients who discontinue any biologic agent treatment due to various reasons such as tolerability concern, complications, economic issue, remission and so on. The impact of this concern has been less studied.

Objectives: The objective of this study was to investigate the reasons and the risk factors for discontinuation any biologic agent in RA patients.

Methods: To include patients who are observed long-term, patients who underwent biologic agent treatment between 2003 and 2007 at Nagoya University Hospital and 12 other institutes (Tsurumi Biologics Communication Study Group) were enrolled. 570 patients who were confirmed continuation or discontinuation of biologic agent treatment were enrolled. The last observation was September 2017. We analyzed the retention rate of biologic agent treatment and the reasons for discontinuation. To identify the risks for discontinuation, baseline demographics were compared between the continuing group and the disc continuing group using Cox hazard regression analysis.

Results: In total 570 patients. The average duration of treatment with biologics was 6.6±3.3 years and total patient-year was 3739 in this study. 458 patients were administrated biologics continuously. 112 patients were withdrawn. Table 1 showed the demographic data in total patients. The retention rate was 96.0% (discontinuation n=23) at least 1 year from starting biologics treatment, 92.6% (n=42) at 3 years, 88.2% (n=67) at 5 years, 84.4% (n=89) at 7 years, 81.1% (n=103) at 10 years and 72.7% (n=112) at 15 years. There were adverse events in 74 patients, lack of effectiveness in 11 patients, others in 27 patients. Comparison of incidence for discontinuation using cumulative hazard function, the reason of adverse events was significantly higher than others reasons.